35 related articles for article (PubMed ID: 20580477)
1. Gadolinium-enhanced cardiovascular magnetic resonance: administered dose in relationship to United States Food and Drug Administration (FDA) guidelines.
Nacif MS; Arai AE; Lima JA; Bluemke DA
J Cardiovasc Magn Reson; 2012 Feb; 14(1):18. PubMed ID: 22376193
[TBL] [Abstract][Full Text] [Related]
2. Responsiveness of Veterans Affairs Health Care System to Zolpidem Safety Warnings.
Kim HM; Gerlach LB; Yosef M; Stano C; Conroy DA; Valenstein M; Pfeiffer PN; Sales AE; Zivin K
J Clin Sleep Med; 2018 Jul; 14(7):1135-1141. PubMed ID: 29991420
[TBL] [Abstract][Full Text] [Related]
3. Delayed Gadolinium Leakage in Ocular Structures on Brain MR Imaging: Prevalence and Associated Factors.
Olatunji R; Lim TR; Jones B; Tafur M; Mathur S; Lin AW; Bharatha A; Suthiphosuwan S
AJNR Am J Neuroradiol; 2023 Dec; 45(1):90-95. PubMed ID: 38123939
[TBL] [Abstract][Full Text] [Related]
4. 2015 Update on Acute Adverse Reactions to Gadolinium based Contrast Agents in Cardiovascular MR. Large Multi-National and Multi-Ethnical Population Experience With 37788 Patients From the EuroCMR Registry.
Bruder O; Schneider S; Pilz G; van Rossum AC; Schwitter J; Nothnagel D; Lombardi M; Buss S; Wagner A; Petersen S; Greulich S; Jensen C; Nagel E; Sechtem U; Mahrholdt H
J Cardiovasc Magn Reson; 2015 Jul; 17(1):58. PubMed ID: 26170152
[TBL] [Abstract][Full Text] [Related]
5. Recent Advances of Manganese-Based Hybrid Nanomaterials for Cancer Precision Medicine.
Liu X; Rong P
Front Oncol; 2021; 11():707618. PubMed ID: 34722253
[TBL] [Abstract][Full Text] [Related]
6. Association Between Contemporary Trends in Inferior Vena Cava Filter Placement and the 2010 US Food and Drug Administration Advisory.
Reddy S; Lakhter V; Zack CJ; Zhao H; Chatterjee S; Bashir R
JAMA Intern Med; 2017 Sep; 177(9):1373-1374. PubMed ID: 28692712
[TBL] [Abstract][Full Text] [Related]
7. An Updated Study to Determine Association between Gadolinium-Based Contrast Agents and Nephrogenic Systemic Fibrosis.
Zhang B; Liang L; Chen W; Liang C; Zhang S
PLoS One; 2015; 10(6):e0129720. PubMed ID: 26076348
[TBL] [Abstract][Full Text] [Related]
8. Changing trends in a decade of vascular radiology-the impact of technical developments of non-invasive techniques on vascular imaging.
Cowell GW; Reid AW; Roditi GH
Insights Imaging; 2012 Oct; 3(5):495-504. PubMed ID: 22865510
[TBL] [Abstract][Full Text] [Related]
9. Manganese-based MRI contrast agents: past, present and future.
Pan D; Schmieder AH; Wickline SA; Lanza GM
Tetrahedron; 2011 Nov; 67(44):8431-8444. PubMed ID: 22043109
[TBL] [Abstract][Full Text] [Related]
10. Gadolinium and nephrogenic systemic fibrosis: have the alarm bells been silenced?
Tamburrini O; Balducci A
Radiol Med; 2012 Feb; 117(1):1-5. PubMed ID: 22020430
[TBL] [Abstract][Full Text] [Related]
11. MRI of the left atrium: predicting clinical outcomes in patients with atrial fibrillation.
Daccarett M; McGann CJ; Akoum NW; MacLeod RS; Marrouche NF
Expert Rev Cardiovasc Ther; 2011 Jan; 9(1):105-11. PubMed ID: 21166532
[TBL] [Abstract][Full Text] [Related]
12. Nephrogenic systemic fibrosis and gadolinium-enhanced magnetic resonance imaging: does a US Food and Drug Administration alert influence practice patterns in CKD?
Martin DR
Am J Kidney Dis; 2010 Sep; 56(3):427-30. PubMed ID: 20728788
[No Abstract] [Full Text] [Related]
13. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines.
Wang Y; Alkasab TK; Narin O; Nazarian RM; Kaewlai R; Kay J; Abujudeh HH
Radiology; 2011 Jul; 260(1):105-11. PubMed ID: 21586680
[TBL] [Abstract][Full Text] [Related]
14. [Nephrogenic systemic fibrosis].
Breitschaft A; Stahlmann R
Med Monatsschr Pharm; 2009 Oct; 32(10):377-82. PubMed ID: 19886227
[TBL] [Abstract][Full Text] [Related]
15. Nephrogenic systemic fibrosis: center case review.
Lauenstein TC; Salman K; Morreira R; Tata S; Tudorascu D; Baramidze G; Singh-Parker S; Martin DR
J Magn Reson Imaging; 2007 Nov; 26(5):1198-203. PubMed ID: 17969162
[TBL] [Abstract][Full Text] [Related]
16. Change in use of gadolinium-enhanced magnetic resonance studies in kidney disease patients after US Food and Drug Administration warnings: a cross-sectional study of Veterans Affairs Health Care System data from 2005-2008.
Kim KH; Fonda JR; Lawler EV; Gagnon D; Kaufman JS
Am J Kidney Dis; 2010 Sep; 56(3):458-67. PubMed ID: 20580477
[TBL] [Abstract][Full Text] [Related]
17. Detection and awareness of moderate to advanced CKD by primary care practitioners: a cross-sectional study from Italy.
Minutolo R; De Nicola L; Mazzaglia G; Postorino M; Cricelli C; Mantovani LG; Conte G; Cianciaruso B
Am J Kidney Dis; 2008 Sep; 52(3):444-53. PubMed ID: 18468747
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
